metastatic triple-negative breast carcinoma Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Female only (3)
Any (1)

Phase 2 (2)
Unknown (2)

Interventional (3)
Observational (1)

Dana-Farber Cancer Institute (1)
Fudan University (1)
Mayo Clinic (1)
Texas Tech University Health Sciences Center, El Paso (1)

No (4)

No (4)

Adult (18+) (4)

I am/have/had

I am/have/hadhair thinning

I am/have/hadcentral nervous system disease

I am/have/hadsystemic chemotherapy

I am/have/hadwhole brain radiotherapy

I am/have/hadprognostic stage iii breast cancer ajcc v8

I am/have/hadbrain metastasis

I am/have/hadchemotherapy regimen

I am/have/hadestrogen receptor

I am/have/hadanticoagulants

I am/have/hadbreast tumor

I am/have/hadalopecia

I am/have/hadHER2

I am/have/hadcancer chemotherapy

I am/have/hadcarcinoma

I am/have/hadcancer

I am/have/hadinvasive breast cancer

I am/have/hadmetastatic triple-negative breast carcinoma

I am/have/hadmonoclonal antibody therapy

I am/have/hadmetastasis

I am/have/hadatezolizumab/nab-paclitaxel

added new label for I am/have/had

I am looking for

I am looking forimmunomodulators

I am looking foreverolimus

I am looking forpyrotinib

I am looking forpaclitaxel

I am looking foradjuvant

I am looking forcorticosteroids

I am looking forimmunostimulant

I am looking formk-3475

I am looking forkeytruda

I am looking formonoclonal antibodies

I am looking foranticoagulants

I am looking foririnotecan

I am looking forpembrolizumab

I am looking forcapecitabine

I am looking forcopper

I am looking forsacituzumab govitecan

I am looking forestrogen

I am looking forprogesterone

I am looking forbisphosphonate

I am looking foratezolizumab

added new label for I am looking for

Advanced Filters

Found 4 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

This is a Phase II, open-label, randomized controlled umbrella trial evaluating the efficacy and safety of multiple targeted treatment in patients with metastaticTNBC.

measurable disease

cancer

targeted therapy

capecitabine

everolimus

0 views
19 Feb, 2024

Cryoablation Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

This early phase I trial studies the side effects and feasibility of cryoablation, atezolizumab, and nab-paclitaxel in treating patients with triple negative breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Cryosurgery, also known as cryoablation …

systemic chemotherapy

paclitaxel

prognostic stage iii breast cancer ajcc v8

chemotherapy regimen

estrogen receptor

0 views
19 Feb, 2024

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

immunomodulators

hair thinning

central nervous system disease

whole brain radiotherapy

brain metastasis

8 views
19 Feb, 2024

Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile

In this study investigators will perform cytokine profiling among patients diagnosed with metastatic triple-negative breast cancer at different time points during the treatment.

cancer

breast cancer

multiple malignancies

metastatic breast cancer

triple-negative breast cancer

0 views
19 Feb, 2024